With more than 20 clients in the GLP-1 medicine class for weight loss and diabetes treatment, OneSource Specialty Pharma aims to be among the first generics to produce semaglutide in Canada and other markets early next year, according to company officials.
This development occurs despite clients Dr. Reddy’s Laboratories and Natco Pharma being involved in a legal patent dispute with Novo Nordisk concerning semaglutide, which is the active component of the weight loss and diabetes medications Wegovy and Ozempic. Novo Nordisk has recently launched Wegovy and cut prices by approximately 37% for some doses, while Ozempic’s introduction in India is still pending.
Next year is expected to witness a surge in generic versions of semaglutide as patents in Canada will expire in January, followed by expirations in other regions, including India, from March.
Neeraj Sharma, Chief Executive Officer and Managing Director of OneSource, expressed confidence that the company, as a contract development and manufacturing organization (CDMO), would be at the forefront with one of its many partners not just in Canada, but in various markets. “The current regulatory situation is very dynamic… Even some of our Indian partners are now anticipating being in the first wave of the launch,” he stated.
Arun Kumar, OneSource’s Founder and Non-Executive Chairperson, clarified the situation regarding the Canada launch, noting that the Canadian market will be the first to open from a market formation perspective. “We strongly believe… this will be the scenario for most players in the Canadian market, if not all. Among the first wave of filers, we have some relationships that will ensure OneSource remains an active participant,” he remarked, emphasizing that the company is not reliant on any single customer or event with 20 clients onboard.
Kumar indicated that over nine customers would be launching the product in various markets outside Canada, with the next two quarters focused on preparing for these launches as per timelines and regulatory approvals. “Several of our eight to nine customers have provided us with take-or-pay and reservation fees,” he noted.
Sharma further elaborated that the upcoming quarters would largely be influenced by the semaglutide approvals from their customers, highlighting significant market potential in regions including Canada, Saudi Arabia, India, Brazil, and others. This reinforces their confidence in a robust financial year 2027, prior to these launches.
The CDMO is enhancing its manufacturing capacity and is considering overseas acquisitions if necessary to meet customer demands. OneSource is investing $100 million in capacity expansion over the next 18 to 24 months, with a substantial portion allocated to upgrading its flagship facility and enhancing its Drug Device Combination capacity for GLP-1 and other key programs. The company reported a revenue of ₹375 crore and a profit of ₹44 crore for the second quarter of 2026.
Published on November 28, 2025.
